Phase 2 Start
AMGN: Phase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
October 31, 2026 · immunoglobulin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 31, 2026
- Company
- AMGEN INC (AMGN)
- Drug
- immunoglobulin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
- Company
- AMGEN INC (AMGN)
- Drug
- immunoglobulin
- Indication
- Immunoglobulin G4-related Disease
Other upcoming events for AMGN
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effica
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb